BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1578 related articles for article (PubMed ID: 19340705)

  • 1. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
    Wildemeersch D; Janssens D; Vrijens M; Weyers S
    Contraception; 2005 Jun; 71(6):465-9. PubMed ID: 15914138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
    Wildemeersch D; Goldstuck ND; Jackers G
    Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of primary and secondary dysmenorrhea with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E; Wildemeersch P
    Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):192-8. PubMed ID: 11848648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in Sweden.
    Marions L; Lövkvist L; Taube A; Johansson M; Dalvik H; Øverlie I
    Eur J Contracept Reprod Health Care; 2011 Apr; 16(2):126-34. PubMed ID: 21417562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The levonorgestrel intrauterine system in nulliparous women.
    Prager S; Darney PD
    Contraception; 2007 Jun; 75(6 Suppl):S12-5. PubMed ID: 17531602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use.
    Rönnerdag M; Odlind V
    Acta Obstet Gynecol Scand; 1999 Sep; 78(8):716-21. PubMed ID: 10468065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system.
    Wildemeersch D; Rowe PJ
    Contraception; 2005 Jun; 71(6):470-3. PubMed ID: 15914139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding.
    Wildemeersch D; Andrade A
    Gynecol Endocrinol; 2010 May; 26(5):383-9. PubMed ID: 20192899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subject and clinician experience with the levonorgestrel-releasing intrauterine system.
    Jensen JT; Nelson AL; Costales AC
    Contraception; 2008 Jan; 77(1):22-9. PubMed ID: 18082662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
    Wildemeersch D; Janssens D; Weyers S
    Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study on the acceptability of levonorgestrel-releasing intrauterine device by young, single, nulliparous Chinese females following surgical abortion.
    Li CF; Lee SS; Pun TC
    Contraception; 2004 Mar; 69(3):247-50. PubMed ID: 14969674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
    Römer T; Linsberger D
    Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
    de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
    Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection and performance of the levonorgestrel-releasing intrauterine system.
    Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
    Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland.
    Backman T; Huhtala S; Tuominen J; Luoto R; Erkkola R; Blom T; Rauramo I; Koskenvuo M
    Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():23-6. PubMed ID: 11336430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas.
    Bahamondes MV; Hidalgo MM; Bahamondes L; Monteiro I
    Contraception; 2011 Nov; 84(5):e11-6. PubMed ID: 22018132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Femilis(®) 60 Levonorgestrel-Releasing Intrauterine System-A Review of 10 Years of Clinical Experience.
    Wildemeersch D; Andrade A; Goldstuck N
    Clin Med Insights Reprod Health; 2016; 10():19-27. PubMed ID: 27547046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.